Furmonertinib (Alflutinib, AST2818) is a potential positive control drug comparable to rifampin for evaluation of CYP3A4 induction in sandwich-cultured primary human hepatocytes
Yali Wu, Yaru Xue, Zitao Guo, Zhendong Chen, Xinyu Ge, Dafang Zhong, Xingxing Diao
Topics & Concepts
CYP3A4PharmacologyEnzyme inducerCytochrome P450Drug metabolismIn vitroChemistryEnzymePharmacokineticsMetaboliteCell cultureDrugBiologyBiochemistryGeneticsPI3K/AKT/mTOR signaling in cancerPharmacogenetics and Drug MetabolismBiochemical and Molecular Research